-
Mashup Score: 0Cognition Therapeutics announces dosing of first patient in MAGNIFY study of CT1812 - 10 month(s) ago
CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 1BLOG: Progression of MGD and why early intervention matters - 10 month(s) ago
Ophthalmology Times – ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
The newest blog on Ophthalmology Times is from Alice Epitropoulos, MD, who discusses meibomian gland dysfunction and why early intervention matters. Read More: https://t.co/9HgxxnGOxl https://t.co/23yl4JmG6m
-
-
Mashup Score: 0
According to researchers at Duke University Medical Center, the tool demonstrates the potential for a non-invasive and inexpensive way to diagnose a common precursor of Alzheimer’s disease.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Duke Health researchers have developed a machine learning model that can differentiate normal cognition from mild cognitive impairment using retinal images from the eye. Read More: https://t.co/Pe7KDElGzj https://t.co/6lX3h2EUFv
-
-
Mashup Score: 0Vantage Surgical Solutions acquires Ophthalmic Surgical Solutions (OSS) - 10 month(s) ago
The Kansas-based company specializes in ophthalmic surgical equipment and services.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Vantage Surgical Solutions has announced the acquisition of Ophthalmic Surgical Solutions (OSS), a Kansas-based company specializing in ophthalmic surgical equipment and services. Read More: https://t.co/HkIJpiEmBK https://t.co/n4Qf9WPy2Z
-
-
Mashup Score: 0Association between visual functioning and death in AMD - 10 month(s) ago
Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
In an observational cohort study, researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD Read More: https://t.co/TKbD4YnyS3 https://t.co/hLLl2GAaZp
-
-
Mashup Score: 1Akari Therapeutics provides update on long-acting PAS-nomacopan candidates for treatment of geographic atrophy - 10 month(s) ago
The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Akari Therapeutics announced it has completed evaluation on long-acting PAS-nomacopan candidates and has selected a version the company plans to take into clinical trials for the treatment of geographic atrophy (GA). Read More: https://t.co/nXCXEvm2DG https://t.co/XzaE7jWw4g
-
-
Mashup Score: 0Severe visual loss in patients with neovascular AMD treated with anti-VEGF therapy related to central macular thickness - 10 month(s) ago
While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Italian researchers reported that severe vision loss can occur often in patients with neovascular age-related macular degeneration (nAMD) between 2 consecutive intravitreal injections of anti-vascular endothelial growth factor therapy. Read More: https://t.co/Ux5mVnsROp https://t.co/UBV21Oso7B
-
-
Mashup Score: 1Astellas, 4DMT sign agreement for use of 4DMT’s proprietary intravitreal R100 vector for rare ophthalmic targets - 10 month(s) ago
According to the companies, R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery. It has the ability to penetrate the internal limiting membrane barrier and to efficiently transduce the entire retina, resulting in robust transgene expression within retinal cells.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Astellas Pharma Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for 1 genetic target implicated in rare monogenic ophthalmic diseases. Read More: https://t.co/Ygc77dRUDs @AstellasUS https://t.co/WWbuzIzkqO
-
-
Mashup Score: 2Screening for diabetic retinopathy: One image says it all - 10 month(s) ago
Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Brazilian clinicians reported that a portable retinal camera combined with artificial intelligence (AI) demonstrated high sensitivity for screening diabetic retinopathy (DR) using only one image per eye. Read More: https://t.co/L7xeACnAz6 https://t.co/fqIzHzlgij
-
-
Mashup Score: 0Cognition Therapeutics announces dosing of first patient in MAGNIFY study of CT1812 - 10 month(s) ago
CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.
Source: Ophthalmology TimesCategories: Latest Headlines, OphthalmologyTweet-
Cognition Therapeutics announced it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an oral therapy for the treatment of geographic atrophy (GA) secondary to dry age-related macular edema (AMD). Read More: https://t.co/wEXRL6ARGS https://t.co/RdTPRsqxwc
-
Cognition Therapeutics announced it has dosed the first participant in the phase 2 MAGNIFY study of CT1812, an oral therapy for the treatment of geographic atrophy (GA) secondary to dry age-related macular edema (AMD). Read More: https://t.co/wEXRL6ARGS https://t.co/xLaTepATaZ